- Home
- BWAY vs ENGN Comparison
BWAY vs ENGN Comparison
Compare BWAY & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWAY
- ENGN
- Stock Information
- Founded
- BWAY 2003
- ENGN 1999
- Country
- BWAY Israel
- ENGN Canada
- Employees
- BWAY N/A
- ENGN N/A
- Industry
- BWAY Medical/Dental Instruments
- ENGN
- Sector
- BWAY Health Care
- ENGN
- Exchange
- BWAY Nasdaq
- ENGN Nasdaq
- Market Cap
- BWAY 201.1M
- ENGN 204.3M
- IPO Year
- BWAY 2019
- ENGN N/A
- Fundamental
- Price
- BWAY $10.96
- ENGN $3.15
- Analyst Decision
- BWAY Strong Buy
- ENGN Buy
- Analyst Count
- BWAY 2
- ENGN 7
- Target Price
- BWAY $14.25
- ENGN $23.29
- AVG Volume (30 Days)
- BWAY 33.7K
- ENGN 75.0K
- Earning Date
- BWAY 08-05-2025
- ENGN 06-12-2025
- Dividend Yield
- BWAY N/A
- ENGN N/A
- EPS Growth
- BWAY N/A
- ENGN N/A
- EPS
- BWAY 0.08
- ENGN N/A
- Revenue
- BWAY $43,457,000.00
- ENGN N/A
- Revenue This Year
- BWAY $351.53
- ENGN N/A
- Revenue Next Year
- BWAY $21.84
- ENGN N/A
- P/E Ratio
- BWAY $54.48
- ENGN N/A
- Revenue Growth
- BWAY 26.86
- ENGN N/A
- 52 Week Low
- BWAY $5.67
- ENGN $2.65
- 52 Week High
- BWAY $12.00
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- BWAY 58.38
- ENGN 37.77
- Support Level
- BWAY $10.81
- ENGN $3.17
- Resistance Level
- BWAY $11.40
- ENGN $3.44
- Average True Range (ATR)
- BWAY 0.46
- ENGN 0.43
- MACD
- BWAY -0.03
- ENGN -0.04
- Stochastic Oscillator
- BWAY 50.88
- ENGN 16.67
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.